BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 30832734)

  • 1. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
    Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
    Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
    Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
    Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
    Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
    Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
    Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
    Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
    J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
    Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
    Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
    Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
    Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
    Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of medulloblastomas with extensive nodularity (MBEN).
    Korshunov A; Sahm F; Stichel D; Schrimpf D; Ryzhova M; Zheludkova O; Golanov A; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2018 Aug; 136(2):303-313. PubMed ID: 29569031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
    Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
    J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
    J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
    Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
    Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.